Hematologic Oncology

Katja Weisel, MD, reviews the study results from the KarMMa study evaluating the use of ide-cel in patients with relapsed/refractory multiple myeloma.

Ola Landgren, MD, PhD, leads a review of the updated efficacy and safety results and subgroup analysis of the CARTITUDE-1 study for patients with relapsed/refractory multiple myeloma.

Leveraging the advances made with liquid biopsies in pantumor assays and specific hematologic cancers has laid the groundwork for the shift in care by using single, or multifaceted approaches for identifying, predicting, and monitoring disease progression.

Closing out their discussion on the management of chronic myeloid leukemia, experts share practical advice and excitement for novel strategies.

Targeted therapies, specifically those agents directed at mutated proteins and aberrant protein-to-protein interactions, have been shown to improve survival among patients with relapsed or refractory acute myeloid leukemia.

A supplemental new drug application has been submitted to the FDA seeking the approval of ibrutinib for the treatment of pediatric and adolescent patients aged 1 year and older with chronic graft-vs-host disease following failure of 1 or more lines of systemic therapy.

Expert hematologist-oncologists review the case of a 56-year-old man with multiple myeloma who received CAR T-cell therapy and share their approaches to treatment.

Katja Weisel, MD, reviews potential mechanisms of resistance to belantamab mafodotin in patients with multiple myeloma, and Sagar Lonial, MD, FACP, discusses potential treatment options for patients who progress on belantamab mafodotin.

Light-chain amyloidosis is a rare plasma cell disorder that involves the production of a misfolded amyloidogenic light chain by a plasma cell clone that deposits in various organs leading to organ failure.

Closing out their discussion on B-cell malignancies, expert panelists share clinical pearls on the management of marginal zone lymphoma.

A comprehensive review of novel therapies in relapsed/refractory marginal zone lymphoma and possible sequencing strategies in this setting.

DLBCL experts share their thoughts on the changing treatment landscape and emerging treatments in large B-cell lymphomas.

Panelists discuss data on the use of CAR T-cell therapies in earlier lines and implications of these data on the DLBCL treatment landscape going forward.

Physicians share key takeaways from the discussion on diagnosis and treatment of immune thrombocytopenia.

ITP experts discuss emerging ITP treatment landscape.

Drs Piatek and Bussel discuss sequencing of therapies in ITP.

Moshe Talpaz, MD, discusses best practices in monitoring patients with CML and applying multidisciplinary care.

Daniel DeAngelo, MD, PhD, provides his perspective on improving CML care through dose adjustment or treatment discontinuation.

Joshua Richter, MD, and Sagar Lonial, MD, FACP, review key ongoing clinical trials with belantamab mafodotin in patients with multiple myeloma and the optimal position for belantamab mafodotin in the myeloma treatment landscape.

Katja Weisel, MD, shares recommended strategies for the prevention and management of potential ocular effects of belantamab mafodotin in multiple myeloma.

Shared insight on frontline treatment approaches for patients diagnosed with marginal zone lymphoma.

Clinical pearls for community physicians regarding the optimal management of patients with follicular lymphoma.

Dr Nowakowski shares data from CD19-targeting monoclonal antibodies in treatment of R/R DLBCL.

Dr Westin discusses real-world data with CAR T-cell therapies in R/R DLBCL that were presented at ASH 2021.

Experts discuss lack of consensus in diagnosis of ITP and challenges physicians face.